Nurix Therapeutics, Inc. (NRIX): Revenue
$83.98M
Year ended 2025-11-30
$36.77M
Trailing 12 months to 2026-05-31
+29.5%
3-year compound annual growth
+36.3%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-11-30 | $83.98M | +54.0% | 2026-01-28, From 2024-12-01 |
| 2024-11-30 | $54.55M | -29.1% | 2026-01-28, From 2023-12-01 |
| 2023-11-30 | $76.99M | +99.3% | 2026-01-28, From 2022-12-01 |
| 2022-11-30 | $38.63M | +29.8% | 2025-01-28, From 2021-12-01 |
| 2021-11-30 | $29.75M | +66.9% | 2023-02-09, From 2020-12-01 |
| 2020-11-30 | $17.82M | -42.7% | 2022-01-28, From 2019-12-01 |
| 2019-11-30 | $31.11M | n/a | 2022-01-28, From 2018-12-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $83.98M | +54.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $84.28M | -5.5% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $85.33M | -6.2% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $82.03M | -46.1% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $81.36M | +14.9% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $88.04M | +376.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $79.95M | +104.9% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $76.20M | -44.8% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $75.13M | +160.6% |
Compare NRIX, SPRY, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗